About the Authors

Thomas J. Moore
Institute for Safe Medication Practices, Alexandria, Virginia, United States of America

Joseph Glenmullen
Department of Psychiatry-Cambridge Hospital, Harvard Medical School, Cambridge, Massachusetts, United States of America

Curt D. Furberg
Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America

Corresponding Author

tmoore@ismp.org

Competing Interests

Mr. Moore has received consulting fees from litigators in cases involving paroxetine, and was an expert witness in a criminal case involving varenicline. Dr. Glenmullen has been retained as an expert witness in cases involving varenicline and psychiatric drugs including antidepressants, antipsychotics, benzodiazepines, mood stablizers, and ADHD drugs. Dr. Furberg has received consulting fees from litigators in cases involving gabapentin. This does not alter the authors' adherence to the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: TJM JG CDF. Performed the experiments: TJM. Analyzed the data: TJM JG CDF. Wrote the paper: TJM JG CDF.